Dexmedetomidine-mediated effects on CAP have been demonstrated to alleviate renal ischaemia–reperfusion injury and LPS-induced acute lung injury in rodent models, decreasing inflammatory mediators (amongst others interleukin [IL]-1β, IL-6, and tumour necrosis factor-alpha [TNF-α]). This evidence concerns the gene IL6 and injury.